Ipamorelin: reported timelines in the literature

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS), also written as ipamorelin acetate in some preparations. It belongs to the growth hormone-releasing peptide (GHRP) family, alongside GHRP-2, GHRP-6 and hexarelin, and is grouped in the literature with GHRH analogues such as sermorelin, tesamorelin and CJC-1295 as an agent intended to modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis [3]. The evidence block supplied for this page does not give a sequence, molecular formula or molecular weight for the compound, so none is stated here.

The work indexed around this compound centres on the growth hormone secretagogue receptor 1a (GHSR-1a) and ghrelin-mimetic signalling [9].

Research Studies

Ipamorelin and post-operative gastrointestinal recovery in human trial protocols

Two registered clinical trial records describe ipamorelin in a surgical recovery context. One protocol states that post-operative administration of ipamorelin is expected to reduce time to recovery of gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection [1]. A separate registered study was designed to determine whether ipamorelin is safe and effective in the management of post-operative ileus [2].

Both entries are registry records describing planned or conducted studies; the evidence block does not report enrolment numbers, comparator results, measured recovery times or completion outcomes. Any timeline figure for GI recovery in humans is therefore not available from this evidence.

Ipamorelin and cisplatin-induced weight loss in ferrets

A study in ferrets examined whether ghrelin mimetics, specifically anamorelin and ipamorelin, could alleviate weight loss and the inhibition of feeding seen during the acute and delayed phases of cisplatin-induced emesis. In that model, the GHSR-1a agonists anamorelin and ipamorelin inhibited cisplatin-induced weight loss, and anamorelin additionally showed anti-emetic effects via a central mechanism [9].

This is an animal model. The reported finding concerns weight loss and feeding behaviour in ferrets, not human body composition, and no human timeline can be inferred from it.

Ipamorelin acetate and the hypothalamic-pituitary-testicular axis in a cichlid fish

A separate study examined ipamorelin acetate in the tilapia Oreochromis mossambicus, a cichlid fish, to assess the impact of the ghrelin agonist on the reproductive axis. The work frames ghrelin as a peptide found in brain and gut that is predicted to play a significant role in the control of various physiological systems in fish, and reports on the administration of ipamorelin acetate in that species [10].

This is a non-mammalian, animal-only line of evidence. It speaks to comparative endocrinology and does not describe human pharmacokinetics or human timelines.

Ipamorelin and the GH-IGF-1 axis in the performance-peptide literature

Review coverage of performance-enhancing drugs marketed as research compounds places ipamorelin among the growth hormone secretagogues most commonly encountered in clinical practice and in online self-administration protocols, in a list that also includes GHRP-2, GHRP-6 and hexarelin [3]. The same body of work describes these peptides collectively as unregulated agents intended to modulate the GH-IGF-1 axis [3].

This literature is descriptive of what is marketed and encountered. It does not supply a validated timeline for any physiological endpoint in humans.

Ipamorelin and peptide therapeutics in gerontology reviews

A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions, targeting hallmarks that include metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline [5]. Ipamorelin sits within the broader peptide-therapeutic field that such reviews survey.

The review is a synthesis rather than a primary timeline study, and the evidence block does not attribute a specific aging-related endpoint or time course to this compound.

Ipamorelin and musculoskeletal or athletic-performance peptide reviews

Reviews of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describe peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and note a parallel gray market of unapproved compounds operating largely outside regulatory oversight [6][7]. Related reviews of peptide supplements in sports medicine note that the market has grown on marketing claims of enhanced performance and accelerated recovery, with these products often perceived as low risk despite the absence of efficacy or safety data [11]. A structured narrative review of injectable peptides in sports medicine similarly reports that clinical adoption has outpaced high-quality evidence and regulatory consensus [12].

These sources describe the regulatory and evidentiary landscape around the compound class. They do not report a measured recovery timeline for ipamorelin in human subjects.

Ipamorelin and measured purity in gray-market research peptides

An evaluation of research-grade peptides marketed directly to consumers assessed purity, measured abundance and endotoxin burden using a large publicly available independent testing dataset, and compared cost against compounded and FDA-approved alternatives; the abstract reports a total of 6441 tested preparations [4]. The same work notes that gray-market peptide use has grown substantially, with patients self-administering compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss and athletic performance enhancement [4].

This evidence concerns product quality and labelling across a market, not the pharmacology or timeline of any single compound. It is relevant to interpreting any self-reported timeline because measured content may not match label content.

Ipamorelin and observational research outside the GH axis

One registered observational study in the evidence block evaluates ibogaine-magnesium, 5-MeO-DMT, magnetic e-resonance therapy and physiological supplementation in Special Operations Forces veterans with PTSD and traumatic brain injury-related cognitive symptoms [8]. It does not concern ipamorelin and is listed here only to note that it is not part of the compound's evidence base.

What the timelines in this literature actually describe

Across the sources supplied, reported time-related content falls into three categories, and none of them is a human pharmacokinetic or effect-onset curve for ipamorelin.

• Registry objectives. The two clinical trial records describe intended endpoints — time to recovery of GI function after bowel resection, and management of post-operative ileus — without reporting measured times [1][2].
• Animal model endpoints. The ferret study reports inhibition of cisplatin-induced weight loss across acute and delayed emesis phases, and the fish study reports effects on the reproductive axis; both are animal-only [9][10].
• Field-level descriptions. Reviews describe the compound class, its marketing and its regulatory status, without attaching a validated human timeline to ipamorelin [3][5][6][7][11][12].

Where a reader encounters a specific number of days or weeks attributed to this compound, that number is not supported by the evidence assembled here. The evidence block contains no human pharmacokinetic parameters, no half-life, no clearance figure and no dose-response timeline for ipamorelin.

Limits of the evidence base

Several constraints should be stated plainly. First, the human-facing entries are trial registry records rather than published results, so they establish that studies were designed around recovery-time endpoints but not what those endpoints measured [1][2]. Second, the mechanistic animal work is in ferrets and in a cichlid fish, species that do not translate directly to human physiology [9][10]. Third, the review literature is largely concerned with the market and regulatory context of the peptide class rather than with primary timeline data for this specific compound [3][4][5][6][7][11][12]. Fourth, the quality-assessment work indicates that consumer-facing research peptide preparations vary in purity and measured abundance, which complicates any attempt to reconcile reported experiences with labelled content [4].

Nothing in the supplied evidence establishes an onset time, a duration of action, or a recovery timeline for ipamorelin in humans.

If you are reading this for personal health reasons

The material described on this page is sold for laboratory research use only, and we do not provide dosing or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician rather than relying on catalogue or review content. This page summarises indexed literature and is not a substitute for professional medical advice.

Sources

• [1] Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function — https://clinicaltrials.gov/study/NCT01280344
• [2] Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus — https://clinicaltrials.gov/study/NCT00672074
• [3] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis — https://europepmc.org/article/PMC/PMC13322892
• [4] Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance — https://doi.org/10.20944/preprints202604.1748.v1
• [5] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
• [6] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
• [7] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
• [8] Trifecta Research Study — https://clinicaltrials.gov/study/NCT07717866
• [9] The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets — https://pubmed.ncbi.nlm.nih.gov/39043357/
• [10] The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus — https://pubmed.ncbi.nlm.nih.gov/38996787/
• [11] Peptide Supplements and Their Therapeutic Applications in Sports Medicine — https://pubmed.ncbi.nlm.nih.gov/42578445/
• [12] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — https://pubmed.ncbi.nlm.nih.gov/42160466/